Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 4/20 | 0.50 |
| ▸ | F10 | P00742 | 13/20 | 0.47 |
| ▸ | MAOB | P27338 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | CALML3 | P27482 | 1/20 | 0.44 |
| ▸ | SDHA | P31040 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4108504 | 1.00 | MAOA (0.50) | MAOAF10MAOBLMNAPTGS1 | |
| SCHEMBL4101695 | 0.90 | MAOA (0.61) | MAOAF10MAOBLMNAPTGS1 | |
| SCHEMBL4097835 | 0.90 | MAOA (0.61) | MAOAF10MAOBLMNAPTGS1 | |
| SCHEMBL4108936 | 0.88 | MAOA (0.50) | MAOAF10MAOBLMNAPTGS1 | |
| SCHEMBL4108932 | 0.88 | MAOA (0.50) | MAOAF10MAOBLMNAPTGS1 | |
| SCHEMBL4101761 | 0.85 | MAOA (0.47) | MAOAF10MAOBLMNAPTGS1 | |
| SCHEMBL4101757 | 0.85 | MAOA (0.47) | MAOAF10MAOBLMNAPTGS1 | |
| SCHEMBL13697542 | 0.85 | MAOA (0.45) | MAOAF10MAOBLMNAPTGS1 | |
| SCHEMBL4101914 | 0.83 | MAOB (0.58) | MAOAMAOBCALML3CYP3A4CYP2C9 | |
| SCHEMBL4101915 | 0.83 | MAOB (0.58) | MAOAMAOBCALML3CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221655-A1 | ANTIBACTERIAL AGENTS | PITZER, INC. (US) | 2009-09-03 | — | — | US | claimed |
| EP-2032565-A2 | BENZISOXAZOLE OXAZOLIDINONES AS ANTIBACTERIAL AGENTS | Pfizer Products Inc. (US) | 2009-03-11 | — | — | EP | claimed |
| WO-2007088438-A2 | BENZISOXAZOLE OXAZOLIDINONES AS ANTIBACTERIAL AGENTS | PFIZER PRODUCTS INC. (US) | 2007-08-09 | — | — | WO | claimed |
| US-20090221655-A1 | ANTIBACTERIAL AGENTS | PITZER, INC. (US) | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221655-A1 | ANTIBACTERIAL AGENTS | OXSR1, CBR3, AOC3 | MAOA 1715/4885F10 1932/4885MAOB 1705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.